LP
PDSB icon

LMR Partners’s PDS Biotechnology PDSB Stock Holding History

LMR Partners’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-17,520
Closed -$108K – 1059
2023
Q1 		$108K Buy
+17,520
New +$143K ﹤0.01% 931
2018
Q3 		– Sell
-2,964
Closed -$61K – 464
2018
Q2 		$61K Buy
+2,964
New +$61.8K ﹤0.01% 456

Other funds holding PDSB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LMR Partners's PDSB Position: Q2 2023 in Review

LMR Partners sold out of PDS Biotechnology (PDSB) in Q2 2023, closing a stake of 17,520 shares — an estimated $108K sold.

LMR Partners first reported a position in PDSB in Q2 2018 and held it in 2 quarters. The position peaked at $108K in Q1 2023. 80 funds tracked by Wall St. Rank hold PDSB as of Q2 2023.

  • LMR Partners reported no remaining PDS Biotechnology position as of Q2 2023 after selling out during the quarter.
  • LMR Partners sold 17,520 PDS Biotechnology shares in Q2 2023, an estimated $108K.
  • LMR Partners first reported a position in PDS Biotechnology in Q2 2018 and held it in 2 quarters.
  • LMR Partners's PDS Biotechnology position peaked at $108K in Q1 2023.
  • 80 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.